Bimatoprost
It is 2015, and therefore finally a good time to write about Bimatoprost. The main reason for this is that at the end of January 2015, Allergan’s phase II clinical trials concerning the use of...
View ArticleBrief Items of Interest, June 2015
Hair loss news first: — The biggest news so far this month is Allergan’s purchase of Kythera Biopharmaceuticals yesterday. While Allergan is largely known for its blockbuster Botox product, for us hair...
View ArticleClik here to view.
Is it Time to buy Allergan (AGN) Stock?
Note: I am no expert in stock market trading and I currently hold no Allergan (AGN) shares in my portfolio. If I were a bit wealthier, I would seriously consider buying a few hundred shares of the...
View ArticleBimatoprost Results are Finally Out
At the beginning of this year, I published a detailed post on Allergan’s Bimatoprost product. In that post, I stated the following: My feeling is that Bimatoprost may result in slightly superior...
View ArticleUpdates from the 2015 WCHR and Related News Items
The 9th World Congress for Hair Research just ended in Miami and there is a surprising lack of online publicly available information regarding key developments. Some companies often publish their...
View ArticleClik here to view.
Lowry and Lowe
In 2017, I covered some important groundbreaking hair loss research from UCLA, led by scientists William Lowry and Heather Christofk. These researchers discovered two topical compounds (RCGD423) and...
View ArticleClik here to view.
Exicure and Allergan
I have covered cosmetics behemoth Allergan (Ireland) many times on this blog in the past. Earlier today, the company entered into a hair loss product related agreement with Exicure (US) that made major...
View Article